Gefitinib hydrochloride (ZD1839 hydrochloride)是一种口服有效的选择性EGFR酪氨酸激酶抑制剂。它能特异性阻断EGFR自磷酸化,抑制EGF刺激的肿瘤细胞生长。此外,该化合物还可诱导细胞自噬并发挥抗肿瘤活性。
|
英文别名 (English Synonym) |
Gefitinib hydrochloride |
|
中文名称 (Chinese Name) |
盐酸吉非替尼 |
|
靶点 (Target) |
EGFR |
|
通路 (Pathway) |
JAK/STAT |
|
CAS号 (CAS NO.) |
184475-55-6 |
|
分子式 (Formula) |
C22H25Cl2FN4O3 |
|
分子量 (Molecular Weight) |
483.36 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15,62(20):5749-54. PMID: 12384534.[2]Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 1,61(19):7184-8. PMID: 11585753.
